Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata - 16/05/19
Doi : 10.1016/j.jaad.2018.11.037
Lucy Y. Liu, MD, Brett A. King, MD, PhD ⁎ 
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
∗Reprint requests: Brett A. King, MD, PhD, Department of Dermatology, Yale University School of Medicine, PO Box 208059, New Haven, CT 06520Department of DermatologyYale University School of MedicinePO Box 208059New HavenCT06520
| Funding sources: Supported by The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research (to Dr King) and Yale University School of Medicine Medical Research Fellowship and the Taylor Opportunity Student Research Fellowship (to Dr Liu). |
|
| Conflicts of interest: Dr King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc; he is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc; and he is on speakers bureau for Pfizer Inc, Regeneron, and Sanofi Genzyme. Dr Liu has no conflicts of interest to disclose. |
© 2018
Publié par Elsevier Masson SAS.
Vol 80 - N° 6
P. 1778-1779 - juin 2019 Retour au numéro
Article précédent
- Alopecia areata and poliosis: A retrospective analysis of 258 cases
- Young Bin Lee, Myungsoo Jun, Won-Soo Lee
- Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
- Lise Boussemart, Adrienne Johnson, Alexa B. Schrock, Sumanta K. Pal, Garrett M. Frampton, David Fabrizio, Zachary Chalmers, Michal Lotem, Geoffrey Gibney, Jeffery Russell, Bartosz Chmielowski, Jeffrey S. Ross, Phil J. Stephens, Vincent A. Miller, Siraj M. Ali
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?